Insmed (INSM) Short term Debt (2012 - 2024)

Insmed (INSM) recorded quarterly Short term Debt of $224.4 million in Q2 2024, little changed quarter-over-quarter from $224.2 million in Q1 2024.

Insmed (INSM) Short term Debt (2012 - 2024) Analysis & Trends

Insmed's Short term Debt history runs 6 years deep, the most recent figure standing at $224.4 million for Q2 2024.

In Q2 2024, Short term Debt changed N/A year-over-year to $224.4 million; the TTM figure through Jun 2024 stood at $224.4 million (changed N/A YoY), while the FY2015 annual figure was $3.1 million, changed N/A from the prior year.
Short term Debt was $224.4 million for Q2 2024 at Insmed, roughly flat from $224.2 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $224.4 million in Q2 2024 to a low of $224.2 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Insmed	19.79 Bn	18.57 Bn	258.54 Mn

Download Data